Jacqueline M Mason

This inventor holds 10 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 3 EPO patents. Top assignee: University Health Network. Active years: 2015-2026.

USPTO Granted Patents = 10 (Patent Applications = 7)

% Patents Active = 90.0

CIPO Patents = 4 (Patent Applications = 13)

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 33(Granted Patents)

Company Filing History:

10 out of 311

University Health Network

patents

Years Active: 2015-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12533357 - Treatment for acute myeloid leukemia or myelodysplastic syndrome (2026-01-27),

2. 12404327 - LILRB3-binding molecules and uses therefor (2025-09-02),

3. 12286476 - FCMR-binding molecules and uses thereof (2025-04-29),

4. 12109215 - Combination therapies for inhibition of polo-like kinase 4 (2024-10-08),

5. 11766437 - Combination therapies for inhibition of TTK protein kinase (2023-09-26),

6. 10875863 - RIPK2 inhibitors and method of treating cancer with same (2020-12-29),

7. 10239881 - RIPK2 inhibitors and method of treating cancer with same (2019-03-26),

8. 9642856 - Treatment for pancreatic cancer (2017-05-09),

9. 9402828 - Methods of targeting PTEN mutant diseases and compositions therefor (2016-08-02),

10. 8933070 - Methods of targeting PTEN mutant diseases and compositions therefor (2015-01-13),

Title: The Innovative Contributions of Jacqueline M Mason

Introduction

Jacqueline M Mason is a prominent inventor based in Toronto, Canada. She has made significant contributions to the field of biomedical research, particularly in the development of novel therapeutic antibodies. With a total of 10 patents to her name, her work has the potential to impact the treatment of various diseases.

Latest Patents

Among her latest patents are the inventions related to LILRB3-binding molecules and FCMR-binding molecules. The LILRB3-binding molecules patent provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods for treating diseases such as cancer, autoimmune diseases, or allergic inflammation. This invention also offers a method to modulate osteoclast differentiation. The FCMR-binding molecules patent similarly introduces novel anti-FCMR antibodies and therapeutic methods for treating cancer and autoimmune diseases.

Career Highlights

Jacqueline M Mason is affiliated with the University Health Network, where she conducts her research and development work. Her innovative approaches and discoveries have positioned her as a key figure in her field, contributing to advancements in medical treatments.

Collaborations

Throughout her career, Jacqueline has collaborated with notable colleagues, including Mark R Bray and Richard Brokx. These partnerships have further enhanced her research capabilities and broadened the impact of her inventions.

Conclusion

Jacqueline M Mason's contributions to the field of biomedical research through her innovative patents demonstrate her commitment to advancing medical science. Her work continues to pave the way for new therapeutic options for patients worldwide.